$HCWB News

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

HCW Biologics Files Prospectus For Resale Of Up To 1,807,228 Shares Underlying Armistice Capital Warrants

HCW Biologics Announces Pricing of $1.5 Million Private Placement

HCW Biologics Prices $1.5M Private Placement Of 903,614 Units At $1.6599 Per Unit

HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics Signs Agreement With Akron Biotech To Commercialize HCW11-006 To Use As Reagent For New Method Of Human CAR-T Cells Production To Treat Cancer

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infections

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

Watching HCW Biologics; Traders Circulate HCW Biologics Peer-Reviewed Journal Of Virology Study Showing HCW9218 Demonstrates Potential To Enhance Immune Responses Against HIV-1, Titled "Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity"

HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

HCW Biologics Prices $1.6M Private Placement Of 618,682 Units At A Price Of $2.5849/Unit

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June 30

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30